BRAF and non-small cell lung carcinoma: Given that oncogenic RAS mutations are upstream activators of RAF signaling and represent another major oncogenic driver in NSCLC, we sought to evaluate exarafenib’s therapeutic potential beyond BRAF-mutated cancers.